MRFR Year End Sale
Conjunctivitis Drugs Market Research Report - Forecast till 2030

Conjunctivitis Drugs Market Research Report: Information by Conjunctivitis Type (Bacterial, Allergic, Viral and Chemical), Drug Class (Antibiotics, Mast Cell Stabilizers, Steroids and others), Route of Administration (Topical, Oral, Intra-Vitreal and others), End Users (Hospitals and Clinics and Specialty Centers) and Region (Americas, Europe, Asia-Pacific and Middle East & Africa) - Forecast till 2030

ID: MRFR/Pharma/1873-HCR | December 2022 | Region: Global | 90 Pages         

Conjunctivitis Drugs Market Speak to Analyst Request a Free Sample

Conjunctivitis Drugs Market Overview


Conjunctivitis Drugs Market size is expected to reach USD 4.45 billion at a CAGR 3.30% during the forecast period 2022-2030. Conjunctivitis is, regularly known as "pink eye," is an aggravation or enlarging of the conjunctiva. The predominance of conjunctivitis or pink eye is expanding internationally, fuelling market development. Conjunctivitis drugs are utilized for the treatment of conjunctivitis. There are different kinds of conjunctivitis, including bacterial, hypersensitive, viral, and synthetic. Conjunctivitis influences a great many individuals and forces financial and social weights. It is assessed that intense conjunctivitis influences around 6 million individuals every year in the US.


The focus point affecting the development of the market incorporates expanding predominance of conjunctivitis. Bacterial conjunctivitis is the second most normal reason and is liable for 50-75% of the cases in kids. It is observed that essential consideration doctors are the primary place of treatment for the greater part of conjunctivitis patients as opposed to eye care experts.


Around 1% of the visits to essential consideration workplaces in the US are related to conjunctivitis. Also, an ascent in cleanliness and mindfulness, developing consumption of wellbeing, more noteworthy openness to allergens and infective specialists, and the infectious idea of the sickness are relied upon to drive the development of the market.


Moreover, factors such as example, proper analysis for viral conjunctivitis and restricted mindfulness with respect to trendsetting innovations are hampering the development of the worldwide market.


Covid-19 Analysis:


The COVID-19 pandemic affected the worldwide Bacterial Conjunctivitis Drugs Market. It impacted the development of the market since, in the primary quarter of 2020, there were a series of lockdowns in major created and arising economies.


The vast majority of the nations in the EU, Korea, Japan, India, China, among others, upheld severe lockdown to contain the spread of the infection. It was started in Wuhan city of, the central area of China, in December 2019. In any case, it came to the north of 200 nations in the next couple of months. As indicated by world meters, over 57.89 million instances of COVID-19 were enlisted till 21st November 2020, with over 1.37 million fatalities around the world.


Market Dynamics:



  • Key Market Drivers:


Further developed eye care framework in clinics and centers around the world


Every one of the medical clinics and facilities is exceptional to treat conjunctivitis. It isn't compulsory to visit specific eye medical clinics to get treated for conjunctivitis sickness. The greater part of conjunctivitis patients is worked by essential consideration specialists instead of specific eye care experts. In the US alone, around 1.0% of all essential consideration office visits are connected with conjunctivitis.


Around 70.0% of the relative multitude of patients with intense conjunctivitis is taken care of in the essential consideration and pressing consideration. There are different eye care emergency clinics, centers, research establishments, among others, that give particular consideration to the patients. For example, Moorfields Eye Hospital, Cleveland Clinic, Wills Eye Hospital, Aravind Eye Care System, ophthalmology facilities, among others, give exceptional eye care to conjunctivitis patients.



  • Market Challenges:


A large number of newborns are getting tainted from bacterial conjunctivitis. New-borns and newborn children who experience the ill effects of this condition are powerless against genuine confusion. Subsequently, treatment of this condition can't be postponed. Every one of the significant emergency clinics, facilities and foundation offer dynamic help to treat newborns immediately.


Balm or endorsed eye drops are recommended for the children subsequent to getting conjunctivitis. Different kinds of conjunctivitis in newborns incorporate compound, bacterial, consideration, and even youth conjunctivitis and may disappear within two or three weeks under the management of the doctors.



  • Market Opportunities:


Expanding medical services consumption


Government strategies from around the globe are considering further developing the medical services framework through expanding medical care spending plans and drafting firm arrangements. The medical services framework is getting support from states around the world. Rising medical care spending has supported the medical care arrangement of the world.


For example, the US spends around $10,000 per person, which is the most elevated medical services spending across the world. Other created economies like the UK, Germany, Canada, among others, put a huge measure of cash in the medical care framework. Indeed, even the rising economies, including China, Korea, India, and Korea, are additionally expanding their medical services consumption.



  • Market Restraints:


Expanding medical care consumption


Government approaches from around the globe are considering further developing the medical services framework through expanding medical care spending plans and drafting firm strategies. The medical care framework is getting support from state-run administrations around the world. Rising medical care spending has helped the medical services arrangement of the world.


For example, the US spends around $10,000 per person, which is the most elevated medical care spending across the world. Other created economies like the UK, Germany, Canada, among others, put a critical measure of cash in the medical services framework. Indeed, even the rising economies, including China, Korea, India, and Korea, are additionally expanding their medical services consumption.


Market Segmentation:


The Conjunctivitis Drugs Market share is portioned in light of conjunctivitis type, drug class, course of organization, end clients, and locale.


The conjunctivitis drugs market, by conjunctivitis type, is fragmented into bacterial, unfavorably susceptible, viral, and substance. The bacterial fragment is additionally ordered into hyperacute bacterial conjunctivitis, intense bacterial conjunctivitis, and persistent bacterial conjunctivitis. The hypersensitive fragment is additionally characterized by atopic keratoconjunctivitis, straightforward unfavorably susceptible conjunctivitis, occasional conjunctivitis, vernal conjunctivitis, and monster papillary conjunctivitis.


As per the conjunctivitis drugs market forecast, this market has the biggest section of the market, as infections cause up to 80% of all instances of intense conjunctivitis. Viral conjunctivitis is more predominant in summer and is the most widely recognized reason for irresistible conjunctivitis across the globe.


Moreover, bacterial conjunctivitis is expected to be the quickest developing section, as around 1.8% to 5.6% of all intense conjunctivitis is brought about by chlamydia. Unfavorably susceptible conjunctivitis influences around 40% of the populace, yet just a few people seek clinical consideration.


Synthetic conjunctivitis represented the least conjunctivitis drugs piece of the pie. Substance conjunctivitis addresses between 11.5-22.1% of visual injury.


In light of medication class, the conjunctivitis drugs market is fragmented into anti-infection agents, pole cell stabilizers, steroids, and others.


In view of the organization, the conjunctivitis drugs market is divided into skin, oral, intra-virtual, and others. The effective anti-infection agent's section represented a significant piece of the pie as these items are best in diminishing the time of conjunctivitis.


In light of the end client, the conjunctivitis drugs market is divided into medical clinics and facilities and specialty focuses.


In the current extent of the review, the sections referenced above are covered in the four worldwide areas, in particular, the Americas, Europe, Asia-Pacific, the Middle East and Africa.


The Conjunctivitis Drugs Market growth in the Americas has additionally been portioned into North America and South America, with the North American market partitioned into the US and Canada. The European conjunctivitis drug market has been divided into Western Europe and Eastern Europe.


Western Europe has been named Germany, France, the UK, Italy, Spain, and the remainder of Western Europe. The conjunctivitis drugs market in Asia-Pacific has been sectioned into Japan, China, India, South Korea, Australia, and the remainder of Asia-Pacific. The conjunctivitis drugs market in the Middle East and Africa has been portioned into the Middle East and Africa.


Regional Analysis:


The Americas ruled the worldwide conjunctivitis drugs market analysis attributable to the rising mindfulness among individuals, the presence of significant makers, the developing reception of internet buying medication expanding predominance of conjunctivitis and others. As per a review, it was observed that around 3 million cases of conjunctivitis happen in the US yearly.


According to the Conjunctivitis Drugs Market outlook, in 2018, Europe was the second-biggest local market. In any case, Asia-Pacific is relied upon to develop with the quickest development rate all through the figure period because of the rising speculations by market players in the district. Then again, the Middle East and Africa hold minimal offers in the worldwide conjunctivitis drugs market because of the low financial turn of events, particularly in Africa.


Competitive Landscape Within the Industry:


A portion of the vital participants working in the conjunctivitis drugs market value is Akorn Pharmaceuticals (US), Alcon/Novartis AG (Switzerland), Allergan Plc (Ireland), Bausch and Lomb (US), Actavis Plc (US), Pfizer Inc (US), Merck and Co. Inc. (US), Lupin Limited (India), and Valeant Pharmaceuticals (Canada).


Recent Market Developments:



  1. June 2021: Santen Pharmaceutical Co, Ltd. reported the USA FDA endorsement of Verkazia for the treatment of vernal keratoconjunctivitis in youngsters and grown-ups within a plan to augment its product offering.

  2. February 2021: Eye Vance Pharmaceuticals, an auxiliary of Santen Pharmaceutical Co. Ltd., went into a vital organization with Hikma Pharmaceuticals PLC for the co-advancement of ZERVIATE in the USA market that is utilized to treat visual tingling related to unfavorably susceptible conjunctivitis.


Report Overview:


The conjunctivitis drugs market trends distinguish, decide, and conjecture the Global Viral Conjunctivitis Drugs Market fragments in view of their sort, sub-type, innovation utilized, applications, end-clients, and locales.



  • Industry to Industry Holds Largest Share in the Viral Conjunctivitis Drugs Market

  • It looks at the miniature business sectors in view of their development patterns, advancement designs, future possibilities, and commitment to the general market.

  • Request from Regional/geological is relied upon to drive the Growth.

  • Rising Adoption of Market Segments in the Viral Conjunctivitis Drugs Growth

  • North America, Europe is relied upon to Witness Higher Growth Rate over the Forecast Period.

  • It concentrates on cutthroat advancements like organizations and joint efforts, consolidations and acquisitions (M&A), innovative work (R&D) exercises, item improvements, and developments in the Global Viral Conjunctivitis Drugs Market.


Key Industrial Segments:


As per the conjunctivitis drugs market forecast, this market has the biggest section of the market, as infections cause up to 80% of all instances of intense conjunctivitis. Viral conjunctivitis is more predominant in summer and is the most widely recognized reason for irresistible conjunctivitis across the globe.


In light of medication class, the conjunctivitis drugs market is fragmented into anti-infection agents, pole cell stabilizers, steroids, and others.


In view of the organization, the conjunctivitis drugs market is divided into skin, oral, intra-virtual, and others. The effective anti-infection agent's section represented a significant piece of the pie as these items are best in diminishing the time of conjunctivitis.


In light of the end client, the conjunctivitis drugs market is divided into medical clinics and facilities and specialty focuses.


In the current extent of the review, the sections referenced above are covered in the four worldwide areas, in particular, the Americas, Europe, Asia-Pacific, the Middle East and Africa.



Report Scope:

Report Attribute/Metric Details
  Market Size   USD 4.45 billion
  CAGR   3.30%
  Base Year   2021
  Forecast Period   2022-2030
  Historical Data   2020
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Conjunctivitis Type, Drug Class, End Users
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   Akorn Pharmaceuticals (US), Alcon/ Novartis AG (Switzerland), Allergan Plc (Ireland), Bausch & Lomb (US), Actavis Plc (US), Pfizer Inc (US), Merck & Co. Inc. (US), Lupin Limited (India), and Valeant Pharmaceuticals (Canada).
  Key Market Opportunities   New product launches and R&D Amongst major key Players
  Key Market Drivers

  • Increasing prevalence of bacterial conjunctivitis.
  • growing expenditure on health.


  • Speak to Analyst Ask for Customization

    Frequently Asked Questions (FAQ) :

    The Global Conjunctivitis Drugs Market is projected grow at approximately 3.30% CAGR during the assessment period (2022-2030).

    Increasing prevalence of bacterial conjunctivitis, growing expenditure on health, and greater exposure to allergens and infective agents are the major tailwinds pushing the growth of the Global Conjunctivitis Drugs Market

    North America holds the largest share in the Global Conjunctivitis Drugs Market, followed by Europe and the Asia Pacific, respectively.

    Alcon/ Novartis AG (Switzerland), Allergan Plc (Ireland), Actavis Plc (US), Akorn Pharmaceuticals (US), Bausch & Lomb (US), Pfizer Inc. (US), Merck & Co. Inc. (US), Lupin Limited (India), and Valeant Pharmaceuticals (Canada), are some of the major players operating in the conjunctivitis drugs market.